WilleH, RequenaJR: The structure of PrP(Sc) prions. Pathogens, 2018; 7:20.
2.
LeeS, KimS, ParkYJ, et al.: The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model. Hum Mol Genet, 2018; 27:2344–2356.
3.
DoYR, KwakJY, KimJA, et al.: Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE). Br J Haematol, 2020; 189:303–312.
4.
PanY, SunL, WangJ, et al.: STI571 protects neuronal cells from neurotoxic prion protein fragment-induced apoptosis. Neuropharmacology, 2015; 93:191–198.
5.
McCormickEM, Zolkipli-CunninghamZ, FalkMJ: Mitochondrial disease genetics update: recent insights into the molecular diagnosis and expanding phenotype of primary mitochondrial disease. Curr Opin Pediatr, 2018; 30:714–724.
6.
SuTP, SuTC, NakamuraY, TsaiSY: The sigma-1 receptor as a pluripotent modulator in living systems. Trends Pharmacol Sci, 2016; 37:262–278.
7.
SzymańskiJ, JanikiewiczJ, MichalskaB, et al.: Interaction of mitochondria with the endoplasmic reticulum and plasma membrane in calcium homeostasis, lipid trafficking and mitochondrial structure. Int J Mol Sci, 2017; 18:1576.
8.
UrferR, MoebiusHJ, SkoloudikD, et al.: Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke. Stroke, 2014; 45:3304–3310.
9.
IlieşiuAM, HodorogeaAS: Treatment of heart failure with preserved ejection fraction. Adv Exp Med Biol, 2018; 1067:67–87.
ZhangN, FengB, MaX, SunK, XuG, ZhouY: Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovasc Diabetol, 2019; 18:107.
13.
CosgroveD, LiuS: Collagen IV diseases: a focus on the glomerular basement membrane in Alport syndrome. Matrix Biol, 2017; 57–58:45–54.
14.
TsimihodimosV, FilippatosTD, ElisafMS: SGLT2 inhibitors and the kidney: effects and mechanisms. Diabetes Metab Syndr, 2018; 12:1117–1123.
15.
DiasMF, JooK, KempJA, et al.: Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives. Prog Retin Eye Res, 2018; 63:107–131.
16.
HuangXF: Current pharmacological concepts in the treatment of the retinitis pigmentosa. Adv Exp Med Biol, 2018; 1074:439–445.
17.
WangG, RajpurohitS, DelaspreF, et al.: First quantitative high-throughput screen in zebrafish identifies novel pathways for increasing pancreatic β-cell Mass. Elife, 2015; 4:e08261.
18.
WhiteDT, ErogluAU, WangG, et al.: ARQiv-HTS, a versatile whole-organism screening platform enabling in vivo drug discovery at high-throughput rates. Nat Protoc, 2016; 11:2432–2453.
19.
ShenT, HuangS: Repositioning the old fungicide ciclopirox for new medical uses. Curr Pharm Des, 2016; 22:4443–4450.
20.
BernierKM, MorrisonLA: Antifungal drug ciclopirox olamine reduces HSV-1 replication and disease in mice. Antiviral Res, 2018; 156:102–106.
21.
HoqueM, Hanauske-AbelHM, PalumboP, et al.: Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology, 2009; 6:90.
22.
ZhuA, LiaoX, LiS, et al.: HBV cccDNA and its potential as a therapeutic target. J Clin Transl Hepatol, 2019; 7:258–262.
23.
KangJA, KimS, ParkM, et al.: Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly. Nat Commun, 2019; 10:2184.
24.
StórustovuSI, EbertB: Pharmacological characterization of agonists at delta-containing GABAA receptors: functional selectivity for extrasynaptic receptors is dependent on the absence of gamma2. J Pharmacol Exp Ther, 2006; 316:1351–1359.
25.
EveringtonEA, GibbardAG, SwinnyJD, SeifiM: Molecular characterization of GABA-A receptor subunit diversity within major peripheral organs and their plasticity in response to early life psychosocial stress. Front Mol Neurosci, 2018; 11:18.
SeegerMA, PallerAS: The role of abnormalities in the distal pathway of cholesterol synthesis in the Congenital Hemidysplasia with Ichthyosiform erythroderma and Limb Defects (CHILD) syndrome. Biochim Biophys Acta, 2014; 1841:345–352.
30.
AtzmonyL, LimYH, HamiltonC, et al.: Topical cholesterol/lovastatin for the treatment of porokeratosis: a pathogenesis-directed therapy. J Am Acad Dermatol, 2020; 82:123–131.
31.
WeaverTE, CalikMW, FarabiSS, et al.: Innovative treatments for adults with obstructive sleep apnea. Nat Sci Sleep, 2014; 6:137–147.
32.
GollaschM, WelshDG, SchubertR: Perivascular adipose tissue and the dynamic regulation of Kv 7 and Kir channels: implications for resistant hypertension. Microcirculation, 2018; 25. DOI: 10.1111/micc.12434
33.
BergT: Kv7(KCNQ)-K(+)-channels influence total peripheral resistance in female but not male rats, and hamper catecholamine release in hypertensive rats of both sexes. Front Physiol, 2018; 9:117.
34.
LiSX, TongYP, XieXC, et al.: Octameric structure of the human bifunctional enzyme PAICS in purine biosynthesis. J Mol Biol, 2007; 366:1603–1614.
35.
ŠkerlováJ, UnterlassJ, GöttmannM, et al.: Crystal structures of human PAICS reveal substrate and product binding of an emerging cancer target. J Biol Chem, 2020:jbc.RA120.013695. [Epub ahead of print]; DOI: 10.1074/jbc.RA120.013695
36.
ShihHJ, KaoMC, TsaiPS, FanYC, HuangCJ: Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study. Prostate Cancer Prostatic Dis, 2017; 20:328–333.
37.
KukkoV, KaipiaA, TalalaK, et al.: Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. Prostate Cancer Prostatic Dis, 2019; 22:483–490.
38.
ChakravarthiBV, GoswamiMT, PathiSS, et al.: Expression and role of PAICS, a de novo purine biosynthetic gene in prostate cancer. Prostate, 2017; 77:10–21.
39.
WalleyKR, ThainKR, RussellJA, et al.: PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med, 2014; 6:258ra143.
40.
ProtoJD, DoranAC, SubramanianM, et al.: Hypercholesterolemia induces T cell expansion in humanized immune mice. J Clin Invest, 2018; 128:2370–2375.
41.
HuangY, PaulWE: Inflammatory group 2 innate lymphoid cells. Int Immunol, 2016; 28:23–28.
42.
YouSY, RuiW, ChenST, et al.: Process of immunogenic cell death caused by disulfiram as the anti-colorectal cancer candidate. Biochem Biophys Res Commun, 2019; 513:891–897.
